Pemphigus Foliaceus: Causes, Diagnosis, and Remission

Pemphigus foliaceus is a rare autoimmune skin disease in which the immune system mistakenly produces antibodies that attack a protein called desmoglein 1, which acts as a kind of glue holding the outermost skin cells together. When that glue fails, the skin blisters and peels in its superficial layers, producing fragile, flaky erosions rather than the deep, raw wounds seen in other forms of pemphigus. It is chronic and can be debilitating, but it is also treatable, and the science around how to manage it has evolved considerably in recent years.

What Happens Inside the Skin

Your skin is built from layers of cells called keratinocytes, and those cells grip each other through specialized junctions. Desmoglein 1 is one of the key adhesion proteins in those junctions, and it is concentrated most heavily in the uppermost part of the epidermis, near the skin’s surface. In pemphigus foliaceus, the immune system generates IgG autoantibodies that target desmoglein 1, disrupting its ability to hold cells together.¹ The cells detach from one another, a process called acantholysis, and fluid fills the gap to form blisters just below the outermost layer of skin.

This explains something important about the disease: because the blisters form so close to the surface, they are extremely fragile. Most people with pemphigus foliaceus never actually see intact blisters on their body. The thin roof of each blister breaks almost immediately, leaving behind shallow erosions, crusts, and scaly patches instead. A related form, pemphigus vulgaris, targets a different adhesion protein (desmoglein 3) concentrated deeper in the epidermis and in mucous membranes, which is why that disease causes deeper blisters and painful mouth sores. In pemphigus foliaceus, the mouth is almost always spared.

How exactly the antibodies cause damage is more nuanced than it first appears. Early thinking assumed the antibodies simply blocked desmoglein 1 from sticking to its partner on a neighboring cell. Research has shown, however, that the antibodies also trigger cellular responses that actively pull the junctions apart, rather than merely sitting in the way.² In other words, the disease involves both a direct hit on the glue and an immune signal that makes the cells actively let go.

Why Blisters Form Where They Do

A concept called the desmoglein compensation hypothesis helps explain the pattern of skin involvement. Desmoglein 1 and desmoglein 3 are distributed differently across the thickness of the epidermis and across different body sites. In pemphigus foliaceus, only desmoglein 1 is under attack. In areas where desmoglein 3 is also present in deeper layers, that backup protein can compensate for the loss of desmoglein 1, keeping the deeper layers intact. That is why lesions in pemphigus foliaceus stay superficial and subcorneal.³ It also explains why mucous membranes, which express desmoglein 3 abundantly, remain unaffected.

The practical result is that pemphigus foliaceus tends to show up on the scalp, face, chest, and upper back first. Many patients describe a pattern that starts on the head and works its way downward. In severe cases, the erosions can spread across most of the body, creating widespread crusting and redness that can look alarming. But even at its worst, the disease stays at the skin surface.

What It Looks Like and How It Is Diagnosed

Because the blisters are so shallow, the typical appearance is scaly, crusted erosions rather than fluid-filled bubbles. Lesions may look like patches of dried, flaking skin, sometimes mistaken early on for eczema, seborrheic dermatitis, or even a bacterial skin infection. Bullous impetigo, a skin infection caused by staphylococcal bacteria, can produce strikingly similar superficial blisters and crusts. One clinical clue is speed: impetigo tends to spread quickly over days, while pemphigus foliaceus usually progresses over weeks to months.⁴

Confirming the diagnosis typically requires a skin biopsy and immunofluorescence testing. A biopsy shows the characteristic superficial split in the epidermis. Direct immunofluorescence of a biopsy sample reveals IgG (and sometimes complement proteins) deposited in a net-like pattern between the epidermal cells. This finding is absent in infections like impetigo and is the single most reliable way to distinguish pemphigus foliaceus from its mimics. Blood tests can detect circulating anti-desmoglein 1 antibodies, and newer diagnostic chip-based assays have demonstrated reasonable accuracy for identifying them, with one validation study reporting about 75% sensitivity and nearly 98% specificity for desmoglein 1 detection in pemphigus foliaceus.⁵

Triggers and Risk Factors

For most patients, pemphigus foliaceus appears without an obvious cause. But several triggers have been identified that can set it off or make it worse.

Certain medications are well-documented triggers. Thiol-containing drugs, most famously penicillamine and captopril, have long been associated with drug-induced pemphigus. In these cases, the drug appears to modify proteins in the skin or disrupt immune regulation in a way that provokes the autoimmune response.⁶ Penicillamine-induced cases have been documented since the 1980s.⁷ More recently, antibiotics like piperacillin-tazobactam and linezolid have been implicated in rare cases. Drug-induced pemphigus sometimes resolves when the offending medication is stopped, but not always.

Sunlight is another known trigger. Ultraviolet radiation appears to enhance the binding of autoantibodies to the epidermis and attract inflammatory cells to sun-exposed skin, which may explain why some patients flare after sun exposure and why lesions often concentrate on sun-exposed areas like the face and upper chest.⁸

The Endemic Form in Brazil

One of the most fascinating chapters in pemphigus foliaceus research involves an endemic variant found in rural Brazil, known locally as fogo selvagem (Portuguese for “wildfire”). This form is clinically and immunologically identical to the sporadic disease seen elsewhere in the world, with the same anti-desmoglein 1 antibodies, but it occurs at dramatically higher rates in certain communities near rivers and streams.

Researchers have linked fogo selvagem to chronic exposure to biting black flies (Simuliidae). A study of environmental risk factors found that exposure to black fly bites carried a nearly fivefold increase in odds of developing the disease.⁹ The hypothesis is that proteins in the flies’ saliva share structural similarities with desmoglein 1, so repeated bites over years gradually train the immune system to produce cross-reactive antibodies. Supporting this idea, research in southeastern Brazil found that pemphigus foliaceus patients and their relatives had significantly higher levels of antibodies against black fly salivary proteins compared to controls, and those antibody levels correlated with anti-desmoglein 1 levels.¹⁰ The correlation was specific: antibodies against mosquito salivary proteins showed no such link.

Genetic susceptibility plays a role too, as certain immune-system gene variants are overrepresented in affected communities. But the environmental component is striking. When indigenous communities have moved away from river areas and black fly habitats, disease incidence has dropped. The endemic form is a vivid example of how an autoimmune disease can be triggered by something in the environment interacting with genetic predisposition.

Pemphigus Erythematosus and Other Variants

A variant worth knowing about is pemphigus erythematosus, sometimes called Senear-Usher syndrome. It combines features of pemphigus foliaceus with features of lupus erythematosus. Patients develop the same superficial blistering and crusting seen in pemphigus foliaceus, but they also have a butterfly-shaped rash on the face and test positive for antibodies associated with lupus. Biopsy shows the intercellular IgG deposition typical of pemphigus alongside a lupus band at the basement membrane zone.¹¹ Pemphigus erythematosus is rare, and it is generally treated along the same lines as pemphigus foliaceus, but its overlap with lupus means patients may need additional monitoring.

Treatment

The backbone of treatment for pemphigus foliaceus has traditionally been systemic corticosteroids, usually prednisone. Corticosteroids suppress the overactive immune response quickly, but they come with a long list of side effects when used at high doses for extended periods, including bone thinning, weight gain, diabetes, and increased infection risk. For that reason, treatment guidelines emphasize adding a steroid-sparing immunosuppressive drug as soon as possible so the corticosteroid dose can be tapered down.

The two most commonly used steroid-sparing agents are azathioprine and mycophenolate mofetil. A systematic review of treatment trials found that azathioprine had a clear steroid-sparing effect, meaning patients could reduce their prednisone dose, though it did not increase the overall rate of remission. Mycophenolate mofetil helped patients reach sustained remission faster and delayed relapses, but its steroid-sparing effect was less clear.¹² In practice, many guidelines recommend one of these two drugs alongside corticosteroids, though the specific dosing and choice of agent are not standardized across countries.¹³

In one study specifically tracking mycophenolate mofetil as an add-on therapy, roughly 45% of pemphigus foliaceus patients achieved full remission, and another 36% achieved partial remission.¹⁴ That leaves a meaningful minority who do not respond adequately, underscoring the need for additional options.

Rituximab and Its Role

Rituximab, a drug that depletes B cells (the immune cells responsible for producing antibodies), has transformed the treatment landscape for pemphigus. Originally developed for lymphoma, it has become a key therapy for moderate-to-severe pemphigus that does not respond well to conventional immunosuppressants. European guidelines now recommend rituximab for moderate to severe pemphigus foliaceus, and case reports have shown that patients can be successfully re-treated after relapse, sometimes years after their initial response.¹⁵

Long-term data comparing rituximab’s effectiveness in pemphigus foliaceus versus pemphigus vulgaris are still somewhat limited, partly because pemphigus foliaceus is less common and therefore harder to study in large numbers. Findings so far support its use in both subtypes, though the evidence base for pemphigus foliaceus specifically remains smaller.¹⁶

Newer Therapies Targeting Antibody Recycling

One of the more exciting developments in pemphigus treatment comes from a class of drugs that target the neonatal Fc receptor, a protein that normally protects IgG antibodies from being broken down and recycled, keeping them circulating in the blood for weeks. By blocking this receptor, these drugs cause a rapid drop in total IgG levels, including the harmful anti-desmoglein 1 antibodies driving the disease.

Efgartigimod, one such drug, showed promising results in a phase II trial that included patients with both pemphigus vulgaris and pemphigus foliaceus. About 90% of patients achieved early disease control after a median of 17 days, and roughly two-thirds reached complete clinical remission with a combination of efgartigimod and a modest dose of prednisone.¹⁷ Another Fc receptor blocker, ALXN1830, produced rapid improvement in disease scores within two weeks in a small pilot study of eight patients, with good tolerability.¹⁸

These are still early-stage findings, and larger, controlled trials are needed. But the speed of response is notable. For a disease where conventional treatment can take months to bring under control, achieving meaningful improvement in two to three weeks represents a real shift. The approach also has an advantage in that it targets antibody levels broadly without the long-lasting immune suppression associated with B-cell depletion.

Prognosis and the Road to Remission

Pemphigus foliaceus is a chronic condition, and for many patients, treatment stretches over years. In a study tracking patients on various corticosteroid-based regimens, about 45% of those with pemphigus foliaceus achieved complete remission off therapy, meaning they could stop all treatment without relapsing, after an average treatment duration of about three years.¹⁹ That is encouraging, but it also means more than half of patients either needed ongoing treatment or had not yet reached that point.

Relapses are common and can be triggered by stress, infections, UV exposure, or medication changes. Many patients go through cycles of flares and remissions over years. The disease itself is rarely fatal in the modern era, but the immunosuppressive treatments carry risks of their own, and managing those side effects is a significant part of long-term care.

Living With Pemphigus Foliaceus

The physical toll of pemphigus foliaceus is obvious, but the psychological burden is easy to underestimate. Visible skin lesions on the face and scalp can be deeply distressing. Studies measuring health-related quality of life in pemphigus patients consistently find significant impairment. In one assessment using standardized quality-of-life tools, patients with pemphigus scored markedly worse than healthy controls on measures of symptoms, emotional distress, and day-to-day functioning, and about 40% screened positive for probable minor psychiatric conditions like depression and anxiety.²⁰

Quality-of-life impairment tracks closely with disease severity. Patients with well-controlled disease report quality-of-life scores close to the general population, while those with significant or extreme disease activity show much lower scores.²¹ The most commonly affected domains include pain and discomfort, mobility limitations, and anxiety or depression. Compared to other chronic skin diseases, the quality-of-life hit from pemphigus is considerable.²² This underscores why aggressive treatment aimed at getting the disease under control quickly is not just a medical priority but also a psychological one.

Pemphigus Foliaceus in Pregnancy

Pregnancy presents a unique situation. The disease can flare during pregnancy, and the antibodies responsible for it are IgG, which can cross the placenta. In pemphigus vulgaris, transient skin lesions in newborns are a recognized phenomenon. In pemphigus foliaceus, neonatal disease is considerably rarer. One case report documented a mother with pemphigus foliaceus who had two consecutive pregnancies: the baby born when the mother had widespread, active disease with high antibody levels developed classic skin lesions, while the baby born during partial remission was unaffected.²³

Several factors seem to protect most newborns. The predominant antibody subtype in pemphigus foliaceus is IgG4, which crosses the placenta less efficiently than other IgG subtypes. The placenta itself contains desmosomal proteins that may act as a sponge, absorbing some of the circulating antibodies before they reach the fetus. And the distribution of desmoglein proteins in newborn skin differs from adult skin: desmoglein 3 is expressed more broadly in the superficial epidermis of neonates, which may compensate for any desmoglein 1 disruption caused by maternal antibodies.²⁴ These protective mechanisms mean that even mothers with severe disease and high antibody titers often deliver healthy infants, but close monitoring during pregnancy is still recommended.